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cholestasis induced by bile duct 
ligation promotes changes in the 
intestinal microbiome in mice
Raul cabrera-Rubio1,2, Angela M. patterson3, Paul D. cotter  1,2 & naiara Beraza3
increasing evidence point to the relevance of intestinal disfunction and changes in the microbiome 
composition during chronic liver disease. More specifically, recent studies have highlighted that 
cholestatic diseases associate with a reduction in the microbiome diversity in patients. Still, the 
dynamics of the changes in the microbiome composition observed, as well as their implication in 
contributing to the pathogenesis of this disease remain largely undefined. Hence, experimental mouse 
models resembling the human pathogenesis are crucial to move forward our understanding on the 
mechanisms underpinning cholestatic disease and to enable the development of effective therapeutics. 
Our results show that the bile duct ligation (BDL) experimental model of cholestasis leads to rapid 
and significant changes in the microbiome diversity, with more than 100 OTUs being significantly 
different in faecal samples obtained from WT mice at 3 days and 7 days after BDL when compared 
to control animals. Changes in the microbial composition in mice after BDL included the enrichment 
of Akkermansia, Prevotella, Bacteroides and unclassified Ruminococcaceae in parallel with a drastic 
reduction of the presence of Faecalibacterium prausnitzii. In conclusion, our results support that bile 
duct ligation induces changes in the microbiome that partly resemble the gut microbial changes 
observed during human cholestatic disease.
Our intestine is home to trillions of microorganisms, including bacteria, archaea, fungi and virus, which can 
be regarded as a superorgan referred to as the gut microbiota, while the gut microbiome refers to the micro-
bial genome. There is increasing evidence of the close relationship between the microbiome and human health. 
Indeed, a number of chronic diseases ranging from atherosclerosis1, diabetes2, metabolic syndrome and obe-
sity3 to neurodegenerative disorders4 have recently been associated with disturbances in the intestinal bacterial 
composition.
Chronic liver disorders have also been associated with changes in gut microbiome composition and the dis-
ruption of the intestinal barrier3,5–8. The ‘leaky gut’ hypothesis proposes that intestinal bacteria, endotoxin or 
other bacterial products translocate from the permeable gut into the liver via the porta circulation, triggering 
hepatic inflammation and fibrosis further contributing to the progression of chronic liver disease5,7.
Recent studies have further supported the association between changes in the microbiome and the progres-
sion of cholestatic liver disease in patients9–14. Cholestasis occurs when the natural flux of bile acids from the liver 
to the gut is impaired, mainly as a result of damage in the biliary ducts, causing accumulation of toxic bile acids 
in the liver that promote cell death, inflammation, fibrogenesis and ultimately cirrhosis and cancer15. Cholestasis 
results from different primary aetiologies but also is a frequent secondary event occurring during most chronic 
liver diseases16. In adults, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the 
main aetiologies causing cholestasis. The available treatments for PBC patients are limited to ursodeoxycholic 
acid (UDCA) and the recently licenced obeticholic acid (OCA) as a second-line approach17,18. Still, a proportion 
of these patients remain unresponsive to treatment. In this line, there is currently no available treatment for PSC 
patients and liver transplantation is the only curative option, which has obvious shortcomings including scarcity 
of donors and a high incidence of recurrence19. Overall, these highlight the urge to find new approaches to treat 
cholestatic patients.
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The use of experimental animal models that resemble human disease is crucial to define the mechanisms 
underpinning the pathogenesis of cholestasis, including the potential role of the microbiome in the progression 
of the disease.
Based on the complexity of the multiple molecular events undergoing during cholestasis, involving interac-
tions between different liver cell types and the gut-microbiome-liver axis, the current consensus is that there is 
not a unique animal model fully recapitulating human cholestatic disease20. While concurring with this conclu-
sion, we here demonstrate that bile duct ligation (BDL) is a plausible model to investigate the functional relevance 
of the microbiome in the pathogenesis of cholestasis. Thus, our in-depth 16S rRNA-based analysis shows that 
BDL induces significant changes in the intestinal microbiome composition of mice, characterised by a reduction 
in diversity at early stages and changes in the abundance of particular bacteria, partially resembling the observa-
tions described during human cholestasis.
Results
Cholestasis induced by bile duct ligation promotes liver injury and inflammation that associ-
ates with increased intestinal permeability. To induce cholestasis, we performed bile duct ligation 
(BDL) in mice that were sacrificed at 3 days and 7 days after surgery. The liver damage serum marker alanine ami-
notransferase (ALT), and the surrogate markers of cholestasis alkaline phosphatase (AP) and bilirubin were sig-
nificantly increased at 3 and 7d after BDL when compared to control mice (Fig. 1A). Histopathological analysis on 
liver sections by H&E staining confirmed the induction of liver damage after BDL as evidenced by the presence of 
wide areas of necrosis at 3d and 7d after surgery (Fig. 1B). Macrophages, as part of the innate immune response, 
are the first line of response against pathogens, including bacterial products (pathogen-associated molecular 
patterns; PAMPs) that translocate from the intestine during cholestasis. FACS analysis on isolated immune cells 
showed a significant increase in the number of liver infiltrated CD11b+/F4/80+ macrophages (Fig. 1C,D).
BDL was associated with changes of the intestinal architecture as observed histologically, including histo-
pathological disruption in the colon with the shortening of crypt length (Fig. 1E,F), epithelial cell atrophy, and 
increase in intraepithelial lymphocytes and immune cell infiltrates (Fig. 1E). Changes in the epithelial cell pop-
ulation in colons from BDL 7d mice were more pronounced, with cellular degradation of luminal epithelial cells 
characterised by vacuoles, blebbing and apoptotic bodies (Fig. 1E).
These structural changes were also associated with increased intestinal permeability in WT mice at 3 and 7 
days after BDL, as evidenced by the presence of circulating FITC in serum samples after gavage administration 
prior to sacrifice (Fig. 1G).
Bile duct ligation promotes early changes in the intestinal microbiome. Microbiome analysis was 
facilitated by 16S rRNA analysis. After quality filtration and length trimming, an average of 116559 (±37266 SD) 
high-quality 16S rRNA sequences were generated per sample and grouped by sample type, i.e., Control: Control 
mice, BDL 3d: Bile duct ligation (after 3 days), BDL 7d: Bile duct ligation (after 7 days).
Fisher’s alpha diversity index showed significant differences between Control vs BDL 3d and BDL 3d vs BDL 
7d groups (P < 0,05; Fig. 2A). Shannon and Simpson alpha diversity index did not change significantly over 
time (Fig. 2A). Notably, significant differences (P = 0.001) in beta diversity, as shown by Principal Coordinates 
Analysis (PCoA) were apparent after BDL in both 3d and 7d groups (Fig. 2B). Here, UniFrac unweighted dis-
tances were calculated by pairwise comparison of the groups of samples, and significant differences were detected 
when the following comparisons were done; Control vs BDL 3d (P < 0.013), Control vs BDL 7d (P < 0.006) and 
BDL 3d vs BDL 7d (P < 0.006) (Fig. 2B).
We found a number of OTUs that were significantly different (P < 0.05) when all groups were compared, 
showing separation as plotted on a heatmap (Fig. 2C). Further analysis showed significant differences in some 
OTUs of interest assigned to genus with lower proportions of Faecalibaculum (including F prausnitzii as identified 
by OTU 321) in the BDL 3d samples, and a transient decrease in the genus Akkermansia in the BDL 3d sample 
group that increases very abruptly in the BDL 7d sample where it shows high values (Fig. 2C). Higher proportions 
of Clostridium (including OTUs 38, 165, 251, 359, 393, 559) in both BDL groups (BDL 3d and BDL 7d) were also 
observed when compared to control samples.
With respect to taxonomy, an average of 613.12 (±66.72 SD) OTUs were obtained, being assigned mainly 
to the phyla Firmicutes, Bacteroidetes and Proteobacteria (Fig. 3A, Supplemental Fig. S1). The differences were 
already at this level, observing higher levels in the ratio Firmicutes/Bacteroidetes (ratio F/B) in the BDL 3d samples 
(ratio F/B = 1.082) compared to the group of control samples (ratio F/B = 0.75) and finally the BDL 7d samples 
(ratio F/B = 0.72) recover the initial ratio.
Further analysis at the family level supported the impact of BDL in promoting changes in the microbi-
ome composition as shown in Fig. 3B, that evidences change in the Porphyromonadaceae, Lachnospiraceae, 
Rikenellaceae, Ruminococcaceae and Prevotellaceae families at 3d and 7d after BDL (Fig. 3B, Supplemental 
Fig. 1B).
The impact of bile duct ligation in promoting changes in the microbiota was also evidenced by a statistically 
significant decrease in proportions of more than 100 OTUs (117 OTUs) when mice subjected to BDL were com-
pared individually to control animals (Fig. 3C). More specifically, as shown in the Venn diagram, 257 OTUs 
(18.9%) were found in the control group, 187 OTUs (13.8%) in BDL 3d group and 149 OTUs (11%) in BDL 7d 
group (Fig. 3D). The core microbiome was composed of 582 OTUs (42.9%). Paired comparisons highlighted 67 
common OTUs (4.9%) to control and BDL 3d samples only, 58 OTUs (4.3%) common to control and BDL 7d 
groups only and another 58 OTUs (4.3%) common to the BDL 3d and BDL 7d groups only (Fig. 3D).
Assessment with linear discrimination analysis (LDA) effect size >2, LefSe (Wilcoxon test) at family level 
showed statistically significant differences when respective pairs of groups were directly compared. More specif-
ically, a significant reduction in unclassified Porphyromonadaceae (p < 0.05) and Sutterellaceae (p < 0.05), as well 
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as an increase of unclassified Ruminococaceae and unclassified Lactobacillaceae in the BDL 3d group compared to 
control samples (Fig. 4A). In addition, we found a reduction of Sutterellaceae (p < 0.05) in BDL 7d samples when 
compared to the control group. Finally, when the BDL 3d and BDL 7d groups were compared, we found greater 
proportions of unclassified Ruminococcaceae (p < 0.05) and unclassified Enterobacteriaceae in BDL 3d group and 
lower presence of Porphyromonadaceae (p < 0.05), which was enriched in BDL 7d samples with respect to the 
BDL 3d samples (Fig. 4A).
At genus level in BDL 3d samples, LDA showed statistically significant increase in the genus Bacteroides 
(p < 0.05) and Parabacteroides (p < 0.05), whereas proportions in the genus Parasutterella (p < 0.05) were 
reduced when compared to controls. Also, we found statistically significant increase in the genus falsiporphyro-
monas (p < 0.05), whereas proportions in the genus Rickenella (p ≤ 0.05), Parasutterella (p < 0.05) and Olsenella 
(p < 0.05) were reduced in BDL 7d samples when compared to controls. Abundance of the Prevotella (p < 0.05) 
genus was increased in samples from BDL 7d mice when compared to BDL 3d samples, while Dialister (p < 0.05) 
and Veillonella (p < 0.05) were more abundant in BDL 3d compared to BDL 7d (Fig. 4B).
In addition, we performed a differential expression analysis based on the Negative Binomial distribution to 
observe statistical changes at the genus level (p < 0.05) with a different approach. We found an increase in the 
genus Akkermansia at 7days after BDL with respect to the other groups of samples (Fig. 4C). The remainder genera 
Figure 1. Effect of BDL in the liver and the intestine. (A) Serum liver damage markers ALT, AP and Bilirubin 
showed increased levels in WT mice 3days and 7 days after BDL. (B) Haematoxylin and Eosin staining on 
liver sections showing profuse necrosis in livers from mice after BDL. (C,D) FACS analysis of immune cells 
isolated from livers showing increased numbers of CD11b/F4/80 cells in livers after BDL. (E) Histopathological 
analysis of colon sections showing tissue damage after BDL and (F) shortening of colon crypts (in microns). (G) 
Detection of FITC in serum samples from mice gavaged with FITC-Dextran 3 hours before sacrifice showing 
increased intestinal permeability. *P < 0.05, **P < 0.01, ***P < 0.001 [Control vs BDL].
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shown in Fig. 4C (Anaerotruncus, Enterococcus, Dialister, Faecalibacterium, Rikenella, Phascolarctobacterium, 
Paraprevotella, Veillonella, Acidaminococcus, Klebsiella, Succinivibrio and Megasphaera) had a statistically signifi-
cantly lower proportion in the BDL 3d and BDL 7d groups compared to control samples.
Discussion
In this study we demonstrate that cholestasis induced by the ligation of the bile duct (bile duct ligation; BDL) 
in mice promotes significant changes in microbiome composition, mainly characterised by a reduction in beta 
diversity.
The role of the microbiome during the pathogenesis of cholestatic liver disease is still poorly understood. 
Recent studies described that cholestatic patients with PSC have an overall less diverse microbiome composi-
tion. The changes described at genera level differ among studies9–12 and include the enrichment in Veillonella, 
Akkermansia, Ruminococcaceae (undefined genus) and Clostridium9 and the decrease in Prevotella10, overall sup-
porting the association between changes in the microbiome and cholestatic disease. Few studies have investigated 
the composition of the microbiome in PBC patients and importantly show some similarities with those observed 
in PSC13,14.
Previous studies showing the benefits of antibiotics in improving liver function in cholestatic patients point to 
an active role of the microbiome in mediating liver injury during cholestasis21. Although these antibiotic-based 
Figure 2. Effects of BDL treatment on the mice microbiome. (A) Fisher, Shannon and Simpson index alpha 
diversity measures of bacterial number and distribution by group. (B) Principal Coordinate analysis (PCoA) 
of unweighted Unifrac distances of generated 16s rRNA sequences highlighting the change in microbial 
composition along the BDL treatment. (C) Bray-Curtis heatmap of beta diversity correlations between samples 
with OTUs significance (p < 0.05). Axes indicate the individual sample per row (right x-axis) and your relation 
with OTUs in the column (bottom y-axis). *P < 0.05 [Control vs BDL; BDL 3d vs BDL 7d].
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treatments have transient benefits in cholestasis patients, antibiotics can induce chronic cholestasis and DILI 
(reviewed in22). In addition, the long-lasting and severe effects that antibiotics have in the microbiome compo-
sition must be carefully considered when used in the clinical practice23,24. Ultimately, the numerous side effects, 
the recurrence when treatment is abandoned and the serious issues of antibiotic-induced microbiota distur-
bances observed in other pathologies, underline the pressing need to find alternative strategies to modulate the 
Figure 3. Effects of BDL treatment on bacterial composition. (A) Phylum level bacterial composition by 
group. (B) Family level bacterial composition by group. (C) OTUs number with possible number of bacteria 
and distribution by group. (D) Venn diagram showing percentage of exclusive OTUs per groups. *P < 0.05, 
***P < 0.001 [Control vs BDL; BDL 3d vs BDL 7d].
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microbiome as a therapeutic approach. Thus, to better understand how changes in the microbiome composition 
and functionality impact on disease progression will enable improved therapeutics for cholestatic patients.
For these reasons, valid experimental animal models resembling the pathogenesis of human cholestasis are 
crucial to gain insight into the mechanisms underlying the progression of this disease and to test therapeutic 
approaches to treat this condition. Currently, there are different cholestasis experimental animal models availa-
ble20, though the consensus is that there is not an ideal model resembling all features of human cholestatic disease. 
Moreover, there are very limited available studies focused on characterising the microbiome composition during 
experimental cholestasis and these studies have shown conflicting results25,26. While Fouts et al.26 described that 
BDL did not alter the microbiome in mice, Alaish et al.25 described changes in Bl6/C57 mice at late stages after 
BDL (14 days) that the authors discussed to be associated with advanced fibrogenesis (cirrhosis).
Figure 4. Statistically significant taxonomic changes in BDL treatment. (A) Linear Discriminant Analysis 
(LDA) Effect Size (LefSe) on 16srRNA sequencing data serts showing differences at family level and (B) genus 
level. (C) Negative binomial GLM fitting and Wald statistics analysis of differences at genus level. All bacteria 
show in LDA graphs are statistically significant. *P < 0.05, **P < 0.01 [Control vs BDL 3d; Control vs BDL 7d; 
BDL 3d vs BDL 7d].
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Our current study supports that indeed, BDL promotes changes in the composition of the microbiome and 
that changes already occur at early stages of the disease, supporting the active role of the microbiome in the 
pathogenesis of this condition. The discrepancy of our results with the Fouts et al. study, where no changes in 
microbial composition were found after BDL, may be better explained by the sample origin; cecal and mucosal 
vs faecal samples used in our present work. Also, the sequencing methodology used in that study was different 
that the one we have applied. Fouts and colleagues used pyrosequencing26 while we used Illumina sequencing 
in our work, which provides a higher number of sequences per sample and greater depth of sequences corre-
sponding to the hypervariable zone V3-V4, as opposed to the hypervariable V1–V3 region targeted in the Fouts 
et al. work26. In addition, microbiome analysis was performed at later timepoints (10 days) after BDL, while our 
analyses comprised earlier timepoints after surgery; 3 and 7 days after BDL. Intriguingly, the Alaish et al.25 study 
described differences at later timepoints after BDL (14d), though it is beyond the scope of our study to explain the 
discrepancy with the Fouts study26.
Interestingly, our results are in line with those found in other models of cholestatic disease like the genetically 
modified Mdr2−/− mice27, which show certain similarities in bacterial composition to mice undergoing BDL, 
including enrichment of Lactobacillus, Prevotella and Clostridiaceae as we show in the present study.
More importantly, some of the changes found during human disease are replicated in mice after BDL as we 
observed a significant enrichment of Akkermansia, in line with the observations in the study by Kummen and col-
leagues9. The abundance of Akkermansia, a mucus degrading bacteria, has been described to negatively correlate 
with obesity in patients28 and mice29 although it is enriched in stool samples from alcohol-induced steatohepatitis 
in mice30. The mucus degrading activity of Akkermansia leads to enhanced mucus production31, which could 
determine its beneficial or detrimental impact on the different disease settings by regulating the thickness of the 
mucus layer. Interestingly, the role of mucins (the glycoproteins that compose the mucus) during liver disease 
remains controversial as mucin deficiency protects from alcohol induced hepatitis in mice32, while enhanced 
mucus thickness relates to improved liver function in other study of experimental ALD33. Interestingly, increased 
mucus thickness has been observed after BDL34 pointing to a role of mucins and likely mucus-degrading bacteria 
during cholestasis.
In this line, we found increased abundance in an unidentified genus of Ruminococcacceae in mice at 3days 
after BDL. Ruminocccaceae are mucin-degrading bacteria that can both influence mucus thickness and glycan 
composition35. Interestingly, it has been recently described that a specific strain of Ruminococcacea (R. gnavus) 
modifies sialic acid in the mucus thus limiting the availability of feed to other bacteria species35. This mechanism 
is particularly relevant in IBD, where an increase in R gnavus has been described35. Future research is guaran-
teed to determine whether the Ruminococcacea species enriched during cholestasis have the relevant enzymatic 
machinery to modify the mucus composition and how this may impact on the mucus layer and the overall intesti-
nal permeability and barrier function. Interestingly, Ruminococcaceae have been found to be enriched in samples 
from fibrotic patients with NAFLD/NASH36,37, supporting their role in the pathogenesis of other chronic liver 
diseases that also associate with impaired intestinal barrier function.
As well, in those studies it was shown that NALFD/NASH in patients associated with increased abundance 
of Bacteroides abundance36,37. Interestingly, Bacteroides (enriched in BDL 3d) increase their abundance when the 
intestinal pH changes from acid to more basic, in detriment of bacteria (e.g. Faecalibacterium prausnitzii) that 
produce butyrate, a short chain fatty acid with well-known beneficial functions in the intestine38,39. The regulation 
of bacterial communities by pH40 could be relevant in the context of cholestasis where the presence of bile acids 
in the intestine decreases.
Accordingly, we found a significant reduction in the abundance of F. prausnitzii in mice after BDL. As a 
butyrate-producer, F. prausnitzzi has anti-inflammatory properties41 and its lower abundance after BDL may 
contribute to the increased permeability and loss of intestinal barrier function during cholestasis. The depletion 
of F prausnitzii in IBD patients3,41,42, including ulcerative colitis43, a condition that closely relates to PSC, further 
supports the impact of the loss of this beneficial bacteria in intestinal function and its potential as a therapeutic 
option to treat these patients44.
Clostridium was increased in BDL 7d samples, which is in agreement with what was found in PSC patients9 
as well as in PBC patients13. In addition to cholestasis, increased abundance of Clostridium has been linked to 
IBD and more specifically, C difficile infection is a common complication of IBD45. Interestingly, Clostridium, 
as well as Bacteroides, associate with increased LPS and liver injury in a mouse model after high fat diet46. In line 
with this, Enterobacteriaceae are also gram negative-LPS producing bacteria with pro-inflammatory activity, 
which abundance is increased in NASH patients when compared to obese47 and in NAFLD/cirrhotics48. Thus, the 
increased abundance of Enterobacteriacea, Clostridium and Bacteroides found after BDL may contribute to the 
overall progression of liver disease by promoting LPS-induced liver injury and inflammation.
Following the observations of Quraishi et al.10, in PSC patients we found reduction of Prevotella in mice at 
3days after BDL though the abundance was increased at the later timepoint (7d). Increased presence of Prevotella 
has been found in cirrhotics49 but most interestingly, Prevotella is distinctively found in the oral cavity. Changes in 
the composition of the oral microbiome and the colonisation of the lower intestinal tract by oral-specific bacteria 
has been related to cirrhosis49. While livers obtained from mice at 7days after BDL do not show evidences of cir-
rhosis (although fibrosis is obvious in these animals50), the increase in Prevotella at this timepoint may be an early 
indicator of the colonisation of the intestinal microbiome with oral-related bacteria. Nevertheless, the reduced 
presence of other oral-related bacteria such as Veillonella, Megasphera and Dialister in BDL mice may indicate 
that this colonisation is gradual in time and likely occurring at later stages of the disease, as BDL 7d showed 
enrichment of Veillonela and Dialister with respect to BDL 3d samples.
Interestingly, our work provides improved statistical results that demonstrate the reduction of the microbiome 
diversity at early stages of cholestasis, while these do not reach statistical significance at later timepoints. This is 
in accordance with previous studies where the diversity of the microbiome was significantly lower in NAFLD 
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patients without fibrosis, whereas the diversity in patients with advanced fibrosis was ‘restored’ to comparable 
levels to healthy individuals48. In line with this, Chen et al.51 found a similar Chao index in cirrhotic patients 
and a non-significant Shannon index when compared to healthy controls. Importantly, the composition of the 
microbiome was altered in all these patients regardless of the lack of statistically significant changes in diversity, 
supporting that significant changes in microbial composition does not necessarily reflect in the overall diversity 
index. A possible explanation to these events could be the so-called ‘Anna Karenina’ principle where stress pro-
motes a stochastic but not deterministic changes in the microbiome composition52. In addition, the emergence of 
opportunistic pathogens at later stages of liver disease, which remain in low abundance in the context of health 
when commensal bacteria dominate the intestinal microbiome may also result in an increased diversity.
Overall, our results support the suitability of the BDL experimental model as an effective tool to investigate 
the role of the microbiome in the progression of cholestasis as well as a platform to test therapeutic approaches 
focused on the modulation of the microbiome, applicable for human disease. Future research will be essential to 
define the causality of the changes in the microbiome as contributors of the progression of cholestatic disease.
Materials and Methods
Experimental procedures in animals. C57/B6J mice were generated at the Disease Model Unit 
(University of East Anglia, UK). All experimental procedures were conducted in male mice from 8–12 weeks 
of age and were approved by the Animal Welfare and Ethical Review Body (AWERB, University of East Anglia, 
Norwich, UK). All experiments were performed following the guidelines of the National Academy of Sciences 
(National Institutes of Health publication 86-23, revised 1985) and were conducted within the provisions of 
the Animals (Scientific Procedures) Act 1986 (ASPA) and the LASA Guiding Principles for Preparing for and 
Undertaking Aseptic Surgery (2010) under UK Home Office approval. Cholestasis was induced by ligating the 
common bile duct (bile duct ligation; BDL) as we previously described50,53.
Histopathological analysis of liver and intestinal tissue. Liver and intestinal tissues were embedded 
in paraffin and further sectioned, dewaxed, hydrated and stained with H&E for pathological analysis.
Flow cytometry. Immune cells were isolated from liver tissues after digestion with collagenase and suc-
cessive washes and Percoll gradient. Isolated immune cells were stained with CD45-APC-Cy7 (BD), CD11b-PE 
(BD) and F4/80-FITC (Myltenyi) antibodies. Flow cytometry analysis was performed using BD LSRFortessa and 
analysed using FlowJo software.
DNA Isolation, sequencing and bioinformatic analysis (16S rRNA gene) from faecal sam-
ples. Fresh faecal pellets were obtained from mice immediately before culling and snap frozen in liquid 
nitrogen. The DNA extraction and sequencing was done according to Gough et al.54. The fastq sequences (from 
Illumina MiSeq platform (2 × 250 bp)) were filtered on the basis of quality (removal of low quality nucleotides at 
the 3′ end) and length (removal of sequences with less than 200 nt) with prinseq55, Paired-end reads with a mini-
mum overlap of 20 bp were joined using Fastq-join56.
The filtered sequences were matched at operational taxonomic unit (OTU; with 97% identity level) using 
UPARSE-OTU algorithm with usearch v7.0 program57 and remove chimeric OTUs against gold database. The 
taxonomic assignment of these OTUs was obtained against the Ribosomal database project (RDP)58.
Statistical analysis. Downstream analyses and graphical outputs the 16S rRNA gene were generated with 
different packages in R59. Alpha diversity was computed with vegan R package60, and was visualized via the phy-
loseq package61, also we use ANOVA and t-test to calculate the significance in the analysis of alpha-diversity 
index. For beta diversity analysis, dissimilarity matrix between samples was calculated with Unifrac Unweight 
method62, studying the effects of treatment and time on microbiota composition variability between samples 
through permutational multivariate analysis of variance (PERMANOVA) with the adonis function and with pair-
wise adonis with FDR corrections. For heatmap we conducted a multivariate analysis using the mvabund package 
(3.9.3)63, using the function anova.manyglm, adjusted for multiple testing, multivariate and univariate results for 
each OTU were obtained. Linear Discriminant Analysis (LDA) Effect Size (LefSe)64 algorithm with LDA effect 
size threshold of 2 (on a log10 scale) was applied after agglomerating data to family and genus level for evidencing 
potential biomarkers linked. Statistical differences between multiple samples at Phylum, Family and Genera-level 
were estimated by Kruskal-Wallis or Mann–Whitney U-test or Negative Binomial distribution65 by adjusted for 
multiple testing according to the method of Benjamini and Hochberg66. Significance (p < 0.05) was based on the 
corrected p-values.
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